Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA

被引:13
作者
Bai, Xianguang [1 ]
Yi, Ming [2 ]
Xia, Xichao [1 ]
Yu, Shengnan [2 ]
Zheng, Xinhua [1 ]
Wu, Kongming [2 ]
机构
[1] Pingdingshan Univ, Med Sch, Pingdingshan 467000, Henan, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan 430030, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
epithelial cell transforming sequence 2; ECT2; non-small cell lung cancer; progression; prognosis; proliferating cell nuclear antigen; PCNA; BREAST-CANCER; ADJUVANT CHEMOTHERAPY; CLINICAL-SIGNIFICANCE; GENE SIGNATURE; SQUAMOUS-CELL; UP-REGULATION; EARLY-STAGE; EXPRESSION; ADENOCARCINOMA; PREDICTION;
D O I
10.2147/CMAR.S170033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Epithelial cell transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor, which is involved in cell division regulation and cell cycle modulation. Recent evidence indicates that ECT2 is overexpressed in many human cancers. However, the exact prognostic value of ECT2 in lung cancer has not been elucidated. Patients and methods: In the current study, we performed correlation and prognosis analyses using public databases and conducted immunohistochemical staining in tissue microarrays, using samples from 204 lung cancer patients with survival data. Results: We found that the expression of ECT2 was markedly increased in lung cancer tissues compared with normal tissues. Moreover, we demonstrated that the expression of ECT2 was related to tumor cell differentiation degree, TNM stage, lymph node metastasis, and prognosis in non-small-cell lung cancer (NSCLC). A correlation analysis indicated that ECT2 levels were significantly correlated with proliferating cell nuclear antigen (PCNA) levels in NSCLC. Furthermore, Kaplan-Meier analyses revealed that high ECT2 expression was associated with unfavorable overall survival (OS) and progression-free survival (PFS) in NSCLC patients. Conclusion: Taken together, these results indicate that the overexpression of ECT2 contributes to tumor invasion and progression, suggesting that ECT2 is a potential prognostic marker for NSCLC patients.
引用
收藏
页码:4039 / 4050
页数:12
相关论文
共 48 条
[1]   Gene Profiling of Clinical Routine Biopsies and Prediction of Survival in Non-Small Cell Lung Cancer [J].
Baty, Florent ;
Facompre, Michael ;
Kaiser, Sergio ;
Schumacher, Martin ;
Pless, Miklos ;
Bubenclorf, Lukas ;
Savic, Spasenija ;
Marrer, Estelle ;
Budach, Wolfgang ;
Buess, Martin ;
Kehren, Jeanne ;
Tamm, Michael ;
Brutsche, Martin H. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (02) :181-188
[2]   Oncogenic pathway signatures in human cancers as a guide to targeted therapies [J].
Bild, AH ;
Yao, G ;
Chang, JT ;
Wang, QL ;
Potti, A ;
Chasse, D ;
Joshi, MB ;
Harpole, D ;
Lancaster, JM ;
Berchuck, A ;
Olson, JA ;
Marks, JR ;
Dressman, HK ;
West, M ;
Nevins, JR .
NATURE, 2006, 439 (7074) :353-357
[3]   Biomarker Discovery in Non-Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation [J].
Botling, Johan ;
Edlund, Karolina ;
Lohr, Miriam ;
Hellwig, Birte ;
Holmberg, Lars ;
Lambe, Mats ;
Berglund, Anders ;
Ekman, Simon ;
Bergqvist, Michael ;
Ponten, Fredrik ;
Koenig, Andre ;
Fernandes, Oswaldo ;
Karlsson, Mats ;
Helenius, Gisela ;
Karlsson, Christina ;
Rahnenfuehrer, Joerg ;
Hengstler, Jan G. ;
Micke, Patrick .
CLINICAL CANCER RESEARCH, 2013, 19 (01) :194-204
[4]   Role of Epithelial Cell Transforming Sequence 2 (ECT2) in Predicting Prognosis of Osteosarcoma [J].
Chen, Zhiguo ;
Liu, Jiatian ;
Zhang, Yihang .
MEDICAL SCIENCE MONITOR, 2017, 23 :3861-3868
[5]   DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells [J].
Chu, Qian ;
Han, Na ;
Yuan, Xun ;
Nie, Xin ;
Wu, Hua ;
Chen, Yu ;
Guo, Mingzhou ;
Yu, Shiying ;
Wu, Kongming .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
[6]   Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines [J].
Coldren, Christopher D. ;
Helfrich, Barbara A. ;
Witta, Samir E. ;
Sugita, Michio ;
Lapadat, Razvan ;
Zeng, Chan ;
Baron, Anna ;
Franklin, Wilbur A. ;
Hirsch, Fred R. ;
Geraci, Mark W. ;
Bunn, Paul A., Jr. .
MOLECULAR CANCER RESEARCH, 2006, 4 (08) :521-528
[7]   Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non-Small-Cell Lung Cancer Including Stage IA Patients [J].
Der, Sandy D. ;
Sykes, Jenna ;
Pintilie, Melania ;
Zhu, Chang-Qi ;
Strumpf, Dan ;
Liu, Ni ;
Jurisica, Igor ;
Shepherd, Frances A. ;
Tsao, Ming-Sound .
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (01) :59-64
[8]   RAS P21 EXPRESSION IN THE PROGRESSION OF BREAST-CANCER [J].
FROMOWITZ, FB ;
VIOLA, MV ;
CHAO, S ;
ORAVEZ, S ;
MISHRIKI, Y ;
FINKEL, G ;
GRIMSON, R ;
LUNDY, J .
HUMAN PATHOLOGY, 1987, 18 (12) :1268-1275
[9]   Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers [J].
Govindan, Ramaswamy ;
Ding, Li ;
Griffith, Malachi ;
Subramanian, Janakiraman ;
Dees, Nathan D. ;
Kanchi, Krishna L. ;
Maher, Christopher A. ;
Fulton, Robert ;
Fulton, Lucinda ;
Wallis, John ;
Chen, Ken ;
Walker, Jason ;
McDonald, Sandra ;
Bose, Ron ;
Ornitz, David ;
Xiong, Donghai ;
You, Ming ;
Dooling, David J. ;
Watson, Mark ;
Mardis, Elaine R. ;
Wilson, Richard K. .
CELL, 2012, 150 (06) :1121-1134
[10]  
Guo JL, 2017, EUR REV MED PHARMACO, V21, P5402, DOI 10.26355/eurrev_201712_13927